The figure is 25 more than previously reported.
The count was updated as part of a rolling review into
Britain's COVID vaccines, with the Medicines and Healthcare products Regulatory
Agency stressing the benefits of the jab "far outweigh any known side
effects".
Concerns have been raised about blood clots after a tiny
proportion of cases among the tens of millions who have received the
Oxford-AstraZeneca jab.
Some countries, such as Germany, have restricted its use to
certain ages but the European medicines watchdog and the World Health
Organisation both say it's safe and effective.
The MHRA said on Thursday there had been "22 reports of
cerebral venous sinus thrombosis (CVST) and 8 reports of other thrombosis
events with low platelets".
The figures cover 9 December 2020 to 21 March this year,
when 15.8 million doses of the AstraZeneca vaccine had been administered, and
around 2.2 million second doses.
The regulator stressed that all medicines have potential
side effects and that the benefits of both COVID jabs means people should not
hesitate to get vaccinated.
"The number and nature of suspected adverse reactions
reported so far are not unusual in comparison to other types of routinely used
vaccines," said the MHRA report.
Its said the most common side effects reported for both the
Pfizer and Oxford-AstraZeneca vaccines were "injection-site
reactions" such as a sore arm, and general flu-like symptoms like
headache, chills, aching, fatigue and nausea.
These are normal reactions to any vaccine as the body
produces an immune response and should disappear after a day or two, said the
MHRA.
It said the side effects are reported more frequently in
younger people.
More than 31 million people in the UK have had a first dose
of one of the vaccines, with second doses topping first doses in recent days as
older people get called up to complete their treatment.
A third approved vaccine, from Moderna, is also expected to
be rolled out in April.
The vaccine rollout in the EU has been much slower and was
hampered by some countries pausing the Oxford-AstraZeneca jab until the
European regulator gave it the green light and concluded it did not increase
the overall number of clots in the population.
Despite that, Germany said this week that it would not give
the vaccine to under-60s on the recommendation of its national regulator.
0 comments:
Post a Comment